Confident Catabasis Takes Positives From Failed Duchenne Trial Into Phase III

 
• By Kevin Grogan

The US biotech has presented positive data from a mid-stage trial of edasalonexent that had previously missed its primary endpoint and hopes the goals it has set for Phase III will be enough to satisfy regulators.

Next Level
Catabasis is putting its DMD drug into Phase III trials • Source: Shutterstock

More from Clinical Trials

More from R&D